Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer.
Blawski R, Vokshi BH, Guo X, Kittane S, Sallaku M, Chen W, Gjyzari M, Cheung T, Zhang Y, Simpkins C, Zhou W, Kulick A, Zhao P, Wei M, Shivashankar P, Prioleau T, Razavi P, Koche R, Rebecca VW, de Stanchina E, Castel P, Chan HM, Scaltriti M, Cocco E, Ji H, Luo M, Toska E.
Blawski R, et al. Among authors: simpkins c.
Cell Rep. 2024 May 2;43(5):114174. doi: 10.1016/j.celrep.2024.114174. Online ahead of print.
Cell Rep. 2024.
PMID: 38700982
Free article.